Results 41 to 50 of about 151,271 (335)

Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.

Translational Andrology and Urology, 2019
Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting men. BPH can lead to a number of symptoms for patients commonly referred to as lower urinary tract symptoms (LUTS). Over the last decade, increased modifiable risk factors,
S. Lokeshwar, Benjamin T. Harper, E. Webb, Andre R. Jordan, T. Dykes, D. Neal, M. Terris, Z. Klaassen   +7 more
semanticscholar   +1 more source

Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera. [PDF]

, 2018
Currently prostate-specific antigen is used for prostate cancer (PCa) screening, however it lacks the necessary specificity for differentiating PCa from other diseases of the prostate such as benign prostatic hyperplasia (BPH), presenting a clinical need
Adusumilli, Ravali, Brooks, James D, Kullolli, Majlinda, Mallick, Parag, Pitteri, Sharon J, Tanimoto, Cheylene, Totten, Sarah M   +6 more
core   +2 more sources

The research progress on multi-omics analysis biomarkers of benign prostatic hyperplasia [PDF]

Yixue xinzhi zazhi
Benign prostatic hyperplasia (BPH) is one of the most common benign diseases among the ageing male population with increasing prevalence, which can cause lower urinary tract symptoms and seriously affect the quality of life of patients.
QIAN Xinhang, GU Jiamin, LU Peiwen, YANG Shisong, FANG Cheng, LI Xiaodong, ZENG Xiantao   +6 more
doaj   +1 more source

Testosterone and benign prostatic hyperplasia

Asian Journal of Andrology, 2015
The use of testosterone to treat the symptoms of late-onset hypogonadal men has increased recently due to patient and physician awareness. However, concerns regarding the effect of testosterone on the prostate, in particular any possible effect on the risk of prostate cancer have prompted further research in this regard.
Jarvis, TR, Chughtai, B, Kaplan, SA
openaire   +5 more sources

Benign prostatic hyperplasia : Part 2-management [PDF]

, 2008
Peer reviewedPublisher ...
N'Dow, James, Wilt, Timothy J
core   +2 more sources

Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population‐based data

BJU International, 2020
To examine national trends in the medical and surgical treatment of benign prostatic hyperplasia (BPH) using Australian Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) population data from 2000 to 2018.
A. Morton, Michael Williams, M. Perera, P. Teloken, P. Donato, S. Ranasinghe, E. Chung, D. Bolton, J. Yaxley, M. Roberts   +9 more
semanticscholar   +1 more source

Effect of heat exposure on viability and contractility of cultured prostatic stromal cells [PDF]

, 2000
Objectives: Different thermotherapeutic modalities such as transurethral microwave therapy or transurethral needle ablation have been developed to provide effective alternatives to surgical management of benign prostate hyperplasia (BPH).
Bartsch, Georg, Boesch, Simone, Corvin, Stefan, Klocker, Helmut, Maneschg, Christoph, Radmayr, Christian   +5 more
core   +1 more source

Expert consensus on Rezūm™: Indications, surgical technique and postoperative care

BJUI Compass
Background Lower urinary tract symptoms associated to benign prostatic hyperplasia (LUTS/BPH) is a growing condition in males associated to a high clinical, economic and humanistic burden.
Emilio López Alcina, Manuel Fernández Arjona, Ester Fernández Guzmán, Jorge Rioja Zuazu, Iván Schwartzman Jochamowitz   +4 more
doaj   +1 more source

HUBUNGAN SINDROM METABOLIK DENGAN BENIGN PROSTATIC HYPERPLASIA (BPH) DI RSUDZA BANDA ACEH [PDF]

, 2017
ABSTRAKSalah satu penyebab Benign Prostatic Hyperplasia (BPH) diduga Sindrom Metabolik (SM). Parameter SM pada penelitian ini berdasarkan konsensus internasional dari International Diabetes Federation (IDF). Tujuan penelitian ini adalah untuk mengetahui
ADE BETRIS AMIGIA
core  

Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (b-turp): evaluation of prostate vascularity and decreased surgical blood loss in large prostates [PDF]

, 2015
Objective: To investigate if short-term treatment with dutasteride (8 weeks) before bipolar transurethral resection of the prostate (B-TURP) can reduce intraoperative bleeding, as dutasteride a dual 5α-reductase inhibitor (5-ARI) blocks the conversion of
Amory, Berry, Boccon-Gibod, Boyle, Carlin, De Berardinis, Delakas, Frye, Hahn, Issa, Kravchick, Ku, Lekas, Madersbacher, Marberger, Marks, Martov, Naslund, Oelke, Pareek, Pareek, Pastore, Puchner, Rittmaster, Roehrborn, Roehrborn, Roehrborn, Toi, Zaitsu   +28 more
core   +1 more source